| scholarly article | Q13442814 |
| P50 | author | David Henry | Q37379128 |
| P2093 | author name string | J Page | |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| public health | Q189603 | ||
| heart failure | Q181754 | ||
| congestive heart failure | Q19000661 | ||
| P304 | page(s) | 777-784 | |
| P577 | publication date | 2000-03-01 | |
| P1433 | published in | JAMA Internal Medicine | Q177428 |
| P1476 | title | Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem | |
| P478 | volume | 160 |
| Q84600264 | Q84600264 |
| Q22306358 | 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines |
| Q49385576 | A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly |
| Q42117920 | A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice |
| Q35206937 | A comparative study of pain in heart failure and non-heart failure veterans |
| Q27678369 | AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin |
| Q37362717 | Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema? |
| Q86212014 | Adverse drug reaction-related hospitalisations among patients with heart failure at two hospitals in the United Arab Emirates |
| Q24681683 | Adverse effects of spinal manipulation: a systematic review |
| Q59150017 | Analysis of ibuprofen, pantoprazole, and itopride combination therapeutic drugs in human plasma by solid phase membrane microtip extraction and high-performance liquid chromatography methods using new generation core shell C18column |
| Q28174940 | Anticoagulation and heart failure |
| Q42769224 | Aspirin, like all other drugs, is a poison |
| Q28196053 | Association between non-steroid antiinflammatory drugs intake and decompensation of heart failure |
| Q36606633 | Association between use of specialty dietary supplements and C-reactive protein concentrations. |
| Q35615269 | Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugs |
| Q46043878 | Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program |
| Q28538368 | Calcium binding-mediated sustained release of minocycline from hydrophilic multilayer coatings targeting infection and inflammation |
| Q34556489 | Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue |
| Q37803337 | Cardiovascular drug therapy in the elderly: benefits and challenges |
| Q28198746 | Cardiovascular hazard of selective COX-2 inhibitors: myth or reality? |
| Q28166985 | Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity |
| Q34730722 | Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis |
| Q36439704 | Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences? |
| Q38164425 | Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC. |
| Q37766887 | Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals |
| Q33953093 | Cause for concern in the use of non-steroidal anti-inflammatory medications in the community--a population-based study |
| Q59125841 | Chemical Speciation of the System Cu(II)-Indomethacin in Ethanol and Water by UV-Vis Spectrophotometry |
| Q48007359 | Chiral separation and modeling of baclofen, bupropion, and etodolac profens on amylose reversed phase chiral column |
| Q34280879 | Chronic non-malignant musculoskeletal pain in older adults: clinical issues and opioid intervention |
| Q33607395 | Clinical and demographic covariates of chronic opioid and non-opioid analgesic use in rural-dwelling older adults: the MoVIES project |
| Q35198206 | Co-morbidity in rheumatoid arthritis |
| Q38717849 | Comorbidities in Heart Failure: Are There Gender Differences? |
| Q34275967 | Comorbidity in rheumatoid arthritis. |
| Q36349740 | Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs |
| Q37947341 | Comparative risks of non-prescription analgesics: a structured topic review and research priorities. |
| Q42613243 | Comparison of changes in blood pressure measurements and antihypertensive therapy in older, hypertensive, ambulatory care patients prescribed celecoxib or rofecoxib |
| Q59481265 | Copper complexes of non-steroidal anti-inflammatory drugs: an opportunity yet to be realized |
| Q34311477 | Cox-2 inhibitors and other nonsteroidal anti-inflammatory drugs in the treatment of pain in the elderly |
| Q34323910 | Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study |
| Q28212127 | Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly? |
| Q28219220 | Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk |
| Q46755095 | Cyclooxygenase inhibition causes marked impairment of renal function in elderly subjects treated with diuretics and ACE-inhibitors |
| Q28192790 | Cyclooxygenase inhibition: between the devil and the deep blue sea |
| Q35179503 | Demographics and concomitant disorders in heart failure |
| Q28079515 | Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO |
| Q81346281 | Diastolic function abnormalities in active rheumatoid arthritis evaluation by conventional Doppler and tissue Doppler: relation with duration of disease |
| Q33941101 | Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study |
| Q37055082 | Diflunisal for ATTR cardiac amyloidosis |
| Q44614902 | Disposition of flurbiprofen in man: influence of stereochemistry and age |
| Q28175558 | Doubt and certainty about nonsteroidal anti-inflammatory drugs in the year 2000: a multidisciplinary expert statement |
| Q84963962 | Drug-induced heart failure |
| Q39204285 | Duration of symptom relief after intra-articular injection of hyaluronic acid combined with sorbitol (anti-ox-vs) in symptomatic hip osteoarthritis |
| Q51146531 | Economic burden of chronic pain. |
| Q34534906 | Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. |
| Q38380512 | Efficacy of celecoxib versus ibuprofen for the treatment of patients with osteoarthritis of the knee: A randomized double-blind, non-inferiority trial |
| Q34939649 | End-of-life care for the hospitalized patient |
| Q37451872 | End-of-life care in heart failure |
| Q34137758 | Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs |
| Q24630778 | Epidemiology and risk profile of heart failure |
| Q37587778 | Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? |
| Q30481876 | Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes |
| Q34771962 | Five easy pieces on evidence based medicine (5). Trading benefit against harm--pain relief vs. adverse effects |
| Q40155507 | Gastrointestinal and Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs |
| Q24669542 | Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans |
| Q77424161 | Gender and drug treatment as determinants of mortality in a cohort of heart failure patients |
| Q35827679 | General practitioners' ranking of evidence-based prescribing quality indicators: a comparative study with a prescription database |
| Q30505423 | Gout and the risk for incident heart failure and systolic dysfunction |
| Q37703574 | Guidance on opioids prescribing for the management of persistent non-cancer pain in older adults |
| Q34485035 | Guided Imagery for Arthritis and Other Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials. |
| Q24795764 | Harpgophytum procumbens for osteoarthritis and low back pain: a systematic review |
| Q36123475 | Heart failure in the oldest patients: the impact of comorbid conditions |
| Q36523260 | Heart failure induced by non-cardiac drugs |
| Q44362970 | High concomitant use of interacting drugs and low use of gastroprotective drugs among NSAID users in an unselected elderly population: a nationwide register-based study |
| Q37799329 | Improving Quality of NSAID Prescribing by Internal Medicine Trainees with an Educational Intervention |
| Q45354251 | Inappropriate prescribing for the elderly--a modern epidemic? |
| Q35825392 | Influence of age on the enantiomeric disposition of ibuprofen in healthy volunteers |
| Q73044943 | Interaction between aspirin and angiotensin-converting enzyme inhibitors: real or imagined |
| Q28193462 | Interaction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure? |
| Q35580134 | Interaction between cyclooxygenase and the renin-angiotensin-aldosterone system: rationale and clinical relevance |
| Q35551913 | Key questions concerning paracetamol and NSAIDs for osteoarthritis. |
| Q38402807 | Managing comorbidities in patients with chronic heart failure: first, do no harm |
| Q38126374 | Medication management of chronic heart failure in older adults |
| Q34165559 | Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events. |
| Q36673018 | Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal |
| Q27009309 | Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs |
| Q26749687 | Non-Steroidal Anti-Inflammatory Drugs and Aspirin Therapy for the Treatment of Acute and Recurrent Idiopathic Pericarditis |
| Q33678007 | Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks |
| Q37257464 | Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials |
| Q35772571 | Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population |
| Q28192227 | Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study |
| Q35083808 | Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors |
| Q84078873 | Non-steroidal anti-inflammatory drugs: use and co-treatment with potentially interacting medications in the elderly |
| Q64121995 | Nonsteroidal Anti-Inflammatory Drugs and Risk of First Hospitalization for Heart Failure in Patients with No History of Heart Failure: A Population-Based Case-Crossover Study |
| Q28079436 | Nonsteroidal Anti-inflammatory Drugs and Risk of Incident Heart Failure: A Systematic Review and Meta-analysis of Observational Studies |
| Q28200864 | Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice |
| Q35091934 | Nonsteroidal anti-inflammatory drugs and heart failure |
| Q37401599 | Nutrition and heart failure: impact of drug therapies and management strategies |
| Q37894486 | Nutrition in cardiovascular disease: salt in hypertension and heart failure |
| Q28508911 | Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II |
| Q34190289 | Optimizing the use of beta-blockers in the effective treatment and management of heart failure: a case study approach |
| Q34229075 | Osteoarthritis management: the role of cyclooxygenase-2-selective inhibitors |
| Q99545920 | Osteoarthritis: Prognosis and emerging therapeutic approach for disease management |
| Q35795138 | Over-the-counter analgesics in older adults: a call for improved labelling and consumer education |
| Q80152218 | P wave dispersion in patients with rheumatoid arthritis: its relation with clinical and echocardiographic parameters |
| Q42702187 | Palliative care and hospice in advanced heart failure |
| Q36247487 | Palliative care for end-stage heart failure |
| Q34001974 | Paracetamol: new vistas of an old drug |
| Q36542638 | Pharmacokinetics of transdermal buprenorphine patch in the elderly |
| Q37025257 | Pharmacologic Management of Osteoarthritis-Related Pain in Older Adults: A Review Shows that Many Drug Therapies Provide Small-to-Modest Pain Relief |
| Q34257433 | Pharmacologic management of osteoarthritis-related pain in older adults. |
| Q44889474 | Pharmacotherapy in congestive heart failure: COX-2 inhibition: a cautionary note in congestive heart failure |
| Q37891877 | Pharmacotherapy of heart failure in the elderly: adverse events |
| Q42966263 | Polypharmacy and pain treatment |
| Q27671971 | Potent Kinetic Stabilizers That Prevent Transthyretin-Mediated Cardiomyocyte Proteotoxicity |
| Q46434625 | Probable cardiac failure due to rofecoxib |
| Q37871285 | Profiling the regulatory lipids: another systemic way to unveil the biological mystery |
| Q45093738 | Prognostic impact of systemic inflammatory diseases in elderly patients with congestive heart failure. |
| Q30919757 | Quality of prescribing for the elderly in Croatia-computerized pharmacy data can be used to screen for potentially inappropriate prescribing. |
| Q35626149 | Rational diuretic management in congestive heart failure: a case-based review |
| Q44537762 | Recommending NSAIDs and paracetamol: A survey of New Zealand physiotherapists' knowledge and behaviours |
| Q28192599 | Relative risk of cardiovascular events in patients with rheumatoid arthritis |
| Q34137765 | Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors |
| Q36615637 | Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. |
| Q36869451 | Review of the selective COX-2 inhibitors celecoxib and rofecoxib: focus on clinical aspects |
| Q34098905 | Rheumatology and musculoskeletal medicine |
| Q36559595 | Safe pharmacologic treatment strategies for osteoarthritis pain in African Americans with hypertension, and renal and cardiac disease. |
| Q34474985 | Safety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease. |
| Q36792634 | Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases |
| Q34305836 | Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs |
| Q24242935 | Single dose oral lumiracoxib for postoperative pain |
| Q24796186 | Single-dose rofecoxib for acute postoperative pain in adults: a quantitative systematic review |
| Q38945834 | Symptom burden in heart failure: assessment, impact on outcomes, and management. |
| Q33973162 | Systematic review: is the use of NSAIDs effective and safe in the elderly? |
| Q37946224 | Systolic heart failure in the elderly: optimizing medical management |
| Q34776806 | The management of hyperuricemia and gout in patients with heart failure |
| Q35585988 | The potential benefits of red beetroot supplementation in health and disease |
| Q36837470 | The problem of polypharmacy in heart failure |
| Q35373720 | The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 gene |
| Q35149318 | The role of opioid analgesics in rheumatoid disease in the elderly population |
| Q35014449 | The safety of drugs for OTC use: what evidence is required for an NSAID switch? |
| Q31013407 | The symptomatic effects of intra-articular administration of hylan G-F 20 on osteoarthritis of the hip: clinical data of 6 months follow-up |
| Q24816687 | Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports |
| Q24654636 | Tramadol extended-release in the management of chronic pain |
| Q44640097 | Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population |
| Q34546560 | Understanding the NSAID related risk of vascular events |
| Q44746153 | Undertreatment of congestive heart failure in an Australian setting |
| Q43981433 | Update of ACR guidelines for osteoarthritis: role of the coxibs |
| Q38249105 | Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes |
| Q21195252 | Use of NSAIDs in treating patients with arthritis |
| Q33906348 | Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community |
| Q35091897 | Use of nonsteroidal anti-inflammatory drugs following exercise-induced muscle injury |
| Q81881480 | Use of tissue Doppler and its comparison with other conventional Doppler techniques in the assessment of diastolic functions in patients with active rheumatoid arthritis |
| Q34221335 | Utilization of potentially inappropriate medications in elderly patients in a tertiary care teaching hospital in India. |
| Q73559007 | Ventricular function abnormalities in active rheumatoid arthritis: a Doppler echocardiographic study |
| Q37320008 | Viscosupplementation with hyaluronic acid in hip osteoarthritis (a review). |
| Q34439681 | What a difference a year makes: reflections on the ACR recommendations for the medical management of osteoarthritis |
| Q43923746 | Worsening heart failure associated with COX-2 inhibitors |
| Q85552886 | [Analgesics in geriatric patients. Adverse side effects and interactions] |
| Q88114055 | [Aortic valve replacement in the elderly] |
| Q54466341 | [Heart insufficiency in the elderly]. |
Search more.